{"article_title": "Actavis closes $70 billion buy of Botox maker Allergan", "article_keywords": ["billion", "closes", "buy", "valeant", "previously", "actavis", "sp", "research", "healthcare", "plan", "70", "allergan", "botox", "company", "maker"], "article_url": "http://www.healthcarefinancenews.com/news/actavis-closes-70-billion-buy-botox-maker-allergan", "article_text": "Dublin-based pharmaceutical giant Actavis on Tuesday said it closed on its $70.5 billion purchase of Allergan, a deal that makes the Irish company one of the top 10 drugmakers in the world.\n\nActavis said the newly combined company, which will take on the Allergan name, is expected to net $23 billion in sales in 2015.\n\n[Also: Tracking 2015 mergers and acquisitions]\n\nAllergan is known most for its cosmetic drug Botox, but also markets brands Restasis, Juvederm, Namenda, Linzess and Lo Loestrin.\n\nActavis previously beat out Valeant in a bidding war for the Botox maker after Valeant said it would cut research allocations under a proposed takeover. Actavis in Tuesday\u2019s announcement said the new company would spend $1.7 billion on research and development.\n\n\u201cOur combined company will be built around a customer-focused commitment to partnering with physicians, pharmacists and patients to deliver innovative treatments and enhance access to important therapies around the world,\u201d Actavis CEO Brent Saunders said in the announcement.\n\nFollow Healthcare Finance on Twitter and LinkedIn.\n\nAllergan CEO David Pyott, however, will not join the board of the new company.\n\nThe $70 billion deal puts it at the top when it comes big deals in healthcare in 2015. Other big deals announced this year include AbbVie\u2019s $21 billion plan to acquire Pharmacyclics and Pfizer\u2019s plan to acquire Hospira for $17 billion.\n\nActivas stock will be added to the S&P 100 index, while American Airlines will replace the spot Allergan previously held on the S&P 500.\n\nTwitter: @HenryPowderly", "article_metadata": {"og": {"url": "http://www.healthcarefinancenews.com/news/actavis-closes-70-billion-buy-botox-maker-allergan", "image": "http://www.healthcarefinancenews.com/sites/healthcarefinancenews.com/files/botoxfeat.jpg", "site_name": "Healthcare Finance News", "description": "Actavis said the newly combined company, which will take on the Allergan name, is expected to net $23 billion in sales in 2015.", "title": "Actavis closes $70 billion buy of Botox maker Allergan"}, "twitter": {"image": {"src": "http://www.healthcarefinancenews.com/sites/healthcarefinancenews.com/files/botoxfeat.jpg"}, "description": "Actavis said the newly combined company, which will take on the Allergan name, is expected to net $23 billion in sales in 2015.", "site": "@HC_Finance", "card": "summary_large_image", "title": "Actavis closes $70 billion buy of Botox maker Allergan"}, "generator": "Drupal 7 (http://drupal.org)", "description": "Dublin-based\u00a0 pharmaceutical giant Actavis on Tuesday said it closed on its $70.5 billion purchase of Allergan, a deal that makes the Irish company one of the top 10 drugmakers in the world.&#13; Actavis said the newly combined company, which will take on the Allergan name,\u00a0 is expected to net $23 billion in sales in 2015.&#13; [Also: Tracking 2015 mergers and acquisitions]", "viewport": "width=device-width; initial-scale=1.0; maximum-scale=1.0; user-scalable=no"}, "_id": "\"57477af36914bd0286fca6ed\"", "article_summary": "Other big deals announced this year include AbbVie\u2019s $21 billion plan to acquire Pharmacyclics and Pfizer\u2019s plan to acquire Hospira for $17 billion.\nActavis previously beat out Valeant in a bidding war for the Botox maker after Valeant said it would cut research allocations under a proposed takeover.\nActivas stock will be added to the S&P 100 index, while American Airlines will replace the spot Allergan previously held on the S&P 500.\nActavis said the newly combined company, which will take on the Allergan name, is expected to net $23 billion in sales in 2015.\nActavis in Tuesday\u2019s announcement said the new company would spend $1.7 billion on research and development."}